Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Pipeline Review, H2 2016

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Pipeline Review, H2 2016
Published Jul 30, 2016
73 pages — Published Jul 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Pipeline Review, H2 2016, provides in depth analysis on Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted pipeline therapeutics.

The report provides comprehensive information on the Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46)
- The report reviews Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics and enlists all their major and minor projects
- The report assesses Beta Secretase 1 (Aspartyl Protease 2 or Beta S

  
Source:
Document ID
GMDHC0440TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables61
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) Overview81
Therapeutics Development93
  Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) Products under Development by Stage of Development91
  Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) Products under Development by Therapy Area101
  Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) Products under Development by Indication111
Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) Pipeline Products Glance122
  Late Stage Products121
  Early Stage Products131
Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) Products under Development by Companies142
Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) Products under Development by Universities/Institutes162
Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) Therapeutics Assessment185
  Assessment by Monotherapy/Combination Products181
  Assessment by Mechanism of Action191
  Assessment by Route of Administration201
  Assessment by Molecule Type212
Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) Companies Involved in Therapeutics Development2310
  Amgen Inc.231
  AstraZeneca Plc241
  Bristol-Myers Squibb Company251
  Eisai Co., Ltd.261
  Eli Lilly and Company271
  Genentech, Inc.281
  Johnson &Johnson291
  Merck &Co., Inc.301
  Novartis AG311
  Vitae Pharmaceuticals, Inc.321
Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) Drug Profiles3326
  AMG-8718 Drug Profile331
  AVCRI-104P3 Drug Profile341
  AVCRI-175P1 Drug Profile351
  AZ-4217 Drug Profile361
  AZD-3293 Drug Profile372
  CNP-520 Drug Profile391
  E-2609 Drug Profile402
  ER-901356 Drug Profile421
  GNE-892 Drug Profile431
  JNJ-54861911 Drug Profile442
  LY-2811376 + LY-3002813 Drug Profile461
  LY-3202626 Drug Profile471
  Oligonucleotides to Activate miR-188-3p for Alzheimer's Disease Drug Profile481
  Small Molecule to Inhibit APP-Selective BACE Enzyme for Alzheimer's Disease Drug Profile491
  Small Molecule to Inhibit BACE 1 for Alzheimer s Disease Drug Profile501
  Small Molecule to Inhibit BACE1 for Alzheimer's Disease Drug Profile511
  Small Molecule to Inhibit BACE1 for Alzheimer s Disease Drug Profile521
  Small Molecules to Inhibit BACE1 for Alzheimer Disease Drug Profile531
  Small Molecules to Inhibit Beta Secretase 1 for Alzheimer's Disease Drug Profile541
  TAK-070 Drug Profile551
  verubecestat Drug Profile562
  VTP-36951 Drug Profile581
Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) Dormant Projects591
Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) Discontinued Products601
Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) Featured News &Press Releases6111
  Jun 14, 2016: New Alzheimer s Study Aimed at Preventing or Delaying Symptoms611
  Apr 08, 2016: AstraZeneca and Eli Lilly and Company announce continuation of pivotal clinical trial for people with early Alzheimer s disease621
  Jan 28, 2016: Merck Completes Enrollment in Pivotal Phase 3 EPOCH Trial Investigating the Efficacy and Safety of Verubecestat in Patients with Mild-to-Moderate Alzheimer s Disease631
  Dec 01, 2014: AstraZeneca and Eli Lilly and Company initiate pivotal clinical trial for patients with early Alzheimer s disease631
  May 07, 2014: AstraZeneca In Discussions For Partnership To Develop Alzheimer's Drug641
  Dec 10, 2013: Merck Advances Development Program for Investigational Alzheimer s Disease Therapy, MK-8931641
  Jul 14, 2013: Merck Presents Findings from Phase 1b Study of Investigational BACE Inhibitor, MK-8931, in Patients with Alzheimer s Disease651
  Apr 24, 2013: GE Healthcare And Eisai To Partner On Alzheimer's Disease Research661
  Dec 03, 2012: Merck Initiates Phase II/III Study of Investigational BACE Inhibitor MK-8931 For Treatment Of Alzheimer's Disease671
  Jul 19, 2012: Eisai Presents First Clinical Data For BACE Inhibitor E2609 At AAIC 2012671
  Jul 13, 2012: Eisai To Present First Clinical Data For Bace Inhibitor E2609 At Alzheimer's Association International Conference 2012681
  Jun 08, 2012: Takeda Announces Transfer Of TAK-070 To National University Corporation691
  Apr 27, 2012: Merck Presents Results Of Phase I Clinical Trial Evaluating Investigational BACE Inhibitor MK-8931 At American Academy Of Neurology701
  Feb 09, 2009: Ligand Earns $1 Million Milestone Payment On Progress Of Drug Candidate For Alzheimer's Disease702
Appendix722
  Methodology721
  Coverage721
  Secondary Research721
  Primary Research721
  Expert Panel Validation721
  Contact Us721
  Disclaimer731

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Pipeline Review, H2 2016" Jul 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Beta-Secretase-1-Aspartyl-Protease-2-or-Beta-Site-Amyloid-Precursor-Protein-Cleaving-Enzyme-1-or-Memapsin-2-or-Membrane-Associated-Aspartic-Protease-2-or-BACE1-or-EC-3-4-23-46-Pipeline-Review-H2-2016-2088-16337>
  
APA:
Global Markets Direct - Market Research. (2016). Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Pipeline Review, H2 2016 Jul 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Beta-Secretase-1-Aspartyl-Protease-2-or-Beta-Site-Amyloid-Precursor-Protein-Cleaving-Enzyme-1-or-Memapsin-2-or-Membrane-Associated-Aspartic-Protease-2-or-BACE1-or-EC-3-4-23-46-Pipeline-Review-H2-2016-2088-16337>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.